Triad Wealth Partners’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$434K Sell
15,222
-3,701
-20% -$98.4K 0.02% 353
2026
Q2
$474K Buy
18,923
+4,785
+34% +$125K 0.03% 330
2026
Q1
$397K Sell
14,138
-6,328
-31% -$168K 0.03% 328
2025
Q4
$510K Buy
20,466
+386
+2% +$9.7K 0.05% 263
2025
Q3
$512K Buy
20,080
+11,316
+129% +$279K 0.07% 203
2025
Q2
$212K Buy
+8,764
New +$204K 0.04% 273
2024
Q3
– Sell
-5,438
Closed -$152K – 659
2024
Q2
$152K Buy
+5,438
New +$150K 0.08% 113

Other funds holding PFE

Triad Wealth Partners's PFE Position: Q3 2026 in Review

Triad Wealth Partners reduced its Pfizer (PFE) stake by 20% in Q3 2026, selling an estimated $98.4K and leaving 15,222 shares worth $434K. The position accounts for 0.02% of the portfolio, ranked #353.

Triad Wealth Partners first reported a position in PFE in Q2 2024 and has held it in 7 quarters since. The position peaked at $512K in Q3 2025. 2,915 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Triad Wealth Partners held 15,222 shares of Pfizer worth $434K as of Q3 2026.
  • Triad Wealth Partners sold 3,701 Pfizer shares in Q3 2026, an estimated $98.4K.
  • Pfizer made up 0.02% of Triad Wealth Partners's portfolio in Q3 2026, its #353 holding.
  • Triad Wealth Partners first reported a position in Pfizer in Q2 2024 and has held it in 7 quarters since.
  • Triad Wealth Partners's Pfizer position peaked at $512K in Q3 2025.
  • 2,915 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Triad Wealth Partners's 13F filing for Q3 2026, filed 26 Oct 2026.